Interaction between warfarin and Panax ginseng in ischemic stroke patients.
作者： Sang-Hun Lee , Young-Min Ahn , Se-Young Ahn , Ho-Kyung Doo , Byung-Cheol Lee
关键词:
摘要: Abstract Background: Today, the combined use of Oriental herbal medicines and Western biomedical has been a prevalent yet controversial practice. Case reports healthy volunteer trials have had conflicting results on effect Panax ginseng warfarin's pharmacologic action, some reporting reductive others potentiating influence. Objective: This study investigated interaction between warfarin P. by observing prothrombin time (PT) international normalized ratio (INR) in ischemic stroke patients who did not history taking warfarin. Design: Randomized, open-label, controlled study. Subjects: Twenty-five (25) newly diagnosed with brain computed tomography or magnetic resonance imaging Korean Medical Hospital, Kyung Hee University (Seoul, Republic Korea). Intervention: Ischemic were randomized into 2 groups: group (n = 12), given both warfarin, control ...
scienceopen.com
liebertonline.com 参考文章(28)
Stephen Erban, Initiation of warfarin therapy: recommendations and clinical pearls. Journal of Thrombosis and Thrombolysis. ,vol. 7, pp. 145- 148 ,(1999) , 10.1023/A:1008833520158
Ann K. Wittkowsky, Drug Interactions Update: Drugs, Herbs, and Oral Anticoagulation Journal of Thrombosis and Thrombolysis. ,vol. 12, pp. 67- 71 ,(2001) , 10.1023/A:1012742628628
Mark W. Linder, Stephen Looney, Jesse E. Adams III, Nancy Johnson, Deborah Antonino-Green, Nichole Lacefield, Bonny L. Bukaveckas, Roland Valdes Jr, Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. Journal of Thrombosis and Thrombolysis. ,vol. 14, pp. 227- 232 ,(2002) , 10.1023/A:1025052827305
Angelo A. Izzo, Edzard Ernst, Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. ,vol. 69, pp. 1777- 1798 ,(2009) , 10.2165/11317010-000000000-00000
Andrew Blann, Jasvinder Hewitt, Fouad Siddiqui, David Bareford, Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. British Journal of Haematology. ,vol. 107, pp. 207- 209 ,(1999) , 10.1046/J.1365-2141.1999.01672.X
Farhad Kamali, Tayyaba Irfan Khan, Barry P King, Richard Frearson, Patrick Kesteven, Peter Wood, Ann K Daly, Hilary Wynne, Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology & Therapeutics. ,vol. 75, pp. 204- 212 ,(2004) , 10.1016/J.CLPT.2003.10.001
Raman Venkataramanan, Bernard Komoroski, Stephen Strom, In vitro and in vivo assessment of herb drug interactions. Life Sciences. ,vol. 78, pp. 2105- 2115 ,(2006) , 10.1016/J.LFS.2005.12.021
Michael K. Ang-Lee, Herbal Medicines and Perioperative Care JAMA. ,vol. 286, pp. 208- 216 ,(2001) , 10.1001/JAMA.286.2.208
David J. Greenblatt, Lisa L. von Moltke, Interaction of Warfarin With Drugs, Natural Substances, and Foods The Journal of Clinical Pharmacology. ,vol. 45, pp. 127- 132 ,(2005) , 10.1177/0091270004271404
Andrea R. Redman, Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy. ,vol. 21, pp. 235- 242 ,(2001) , 10.1592/PHCO.21.2.235.34106